TLR3-specific RNA agonist ARNAX could activate tumor-specific CTLs, and overcome anti-PD-1 resistance without cytokinemia when combined with anti-PD-L1 antibody and a tumor-associated antigen [101]. The gene discussed is TLR3; the disease is neoplasm.